Alder Biopharmaceuticals Inc (ALDR) : Birchview Capital Lp added new position in Alder Biopharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 5,150 shares of Alder Biopharmaceuticals Inc which is valued at $156,663 , the company said in a statement filed on Aug 9, 2016 with the SEC.Alder Biopharmaceuticals Inc makes up approximately 0.10% of Birchview Capital Lp’s portfolio.
Other Hedge Funds, Including , Brown Advisory Inc boosted its stake in ALDR in the latest quarter, The investment management firm added 45,816 additional shares and now holds a total of 426,490 shares of Alder Biopharmaceuticals Inc which is valued at $12,973,826. Alder Biopharmaceuticals Inc makes up approx 0.04% of Brown Advisory Inc’s portfolio.
Alder Biopharmaceuticals Inc opened for trading at $30.26 and hit $30.57 on the upside on Wednesday, eventually ending the session at $30.29, with a gain of 0.50% or 0.15 points. The heightened volatility saw the trading volume jump to 2,93,548 shares. Company has a market cap of $1,520 M.
On the company’s financial health, Alder Biopharmaceuticals Inc reported $-0.76 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.72.Analysts expectations of $ .14.During the same quarter in the previous year, the company posted $-0.40 EPS.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.